Cargando…
2751. Cefiderocol Use in Treating Patients with Confirmed Stenotrophomonas maltophilia Infections in US Hospitals During January 2020 - June 2022
BACKGROUND: Stenotrophomonas maltophilia (SM) infections have been associated with high mortality rates (21% to 69%), particularly in critically ill patients because of SM inherent resistance to many antibiotics, including carbapenems. This study describes cefiderocol (CFDC) treating hospitalized pa...
Autores principales: | Cai, Bin, Nguyen, Sean T, Copeland, Jennifer D, Song, Hyun Jin, Slover, Christine M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10679100/ http://dx.doi.org/10.1093/ofid/ofad500.2362 |
Ejemplares similares
-
2753. Real-World Use of Cefiderocol Treating Non-COVID Patients with Confirmed Gram-Negative Infections in US Hospitals During January 2020-June 2022
por: Cai, Bin, et al.
Publicado: (2023) -
2752. Outcomes of Patients with Stenotrophomonas maltophilia infections treated with Cefiderocol in PROVE (Retrospective Cefiderocol Chart Review) Study
por: Marcella, Stephen, et al.
Publicado: (2023) -
In Vitro Activity and In Vivo Efficacy of Cefiderocol against Stenotrophomonas maltophilia
por: Nakamura, Rio, et al.
Publicado: (2021) -
Successful Treatment of Persistent Stenotrophomonas maltophilia Bacteremia With Cefiderocol in an Infant
por: Hsu, Alice J, et al.
Publicado: (2023) -
Efficacy of Cefiderocol in Experimental Stenotrophomonas maltophilia Pneumonia in Persistently Neutropenic Rabbits
por: Petraitis, Vidmantas, et al.
Publicado: (2022)